XML 20 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (shares) at Dec. 31, 2014   23 60,741,082        
Beginning balance at Dec. 31, 2014 $ 111,537,594 $ 0 $ 60,741 $ 443,327,915 $ (331,910,290) $ (251,390) $ 310,618
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     10,925,000        
Issuance of common stock for cash, net of financing costs 81,902,363   $ 10,925 81,891,438      
Payment to minority stockholders (149,559)           (149,559)
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     551,883        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 2,598,915   $ 552 2,598,363      
Stock-based compensation 6,186,848     6,186,848      
Net loss attributable to common stockholders (29,102,837)       (29,187,606)   84,769
Unrealized gain (loss) on short-term investments, net of tax 7,528         7,528  
Unrealized gain (loss) on investment in affiliated entity, net of tax 2,952,201         2,952,201  
Ending balance (shares) at Dec. 31, 2015   23 72,217,965        
Ending balance at Dec. 31, 2015 175,933,053 $ 0 $ 72,218 534,004,564 (361,097,896) 2,708,339 245,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     658,748        
Issuance of common stock for cash, net of financing costs 6,295,761   $ 659 6,295,102      
Issuance of common stock for Bioject acquisition (shares)     440,122        
Issuance of common stock for Bioject acquisition 4,300,000   $ 440 4,299,560      
Payment to minority stockholders (149,559)           (149,559)
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     450,045        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,640,740   $ 449 1,640,291      
Cashless exercise of stock options and warrants (shares)     295,490        
Cashless exercise of stock options and warrants 0   $ 296 (296)      
Stock-based compensation 10,479,135     10,479,135      
Net loss attributable to common stockholders (73,740,339)       (73,740,339)    
Unrealized gain (loss) on short-term investments, net of tax (111,967)         (111,967)  
Unrealized gain (loss) on investment in affiliated entity, net of tax (1,268,404)         (1,268,404)  
Ending balance (shares) at Dec. 31, 2016   23 74,062,370        
Ending balance at Dec. 31, 2016 123,378,420 $ 0 $ 74,062 556,718,356 (434,838,235) 1,327,968 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of accounting change 0     312,310 (312,310)    
Issuance of common stock for cash, net of financing costs (shares)     15,437,406        
Issuance of common stock for cash, net of financing costs 94,347,922   $ 15,437 94,332,485      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     857,868        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,342,250   $ 859 1,341,391      
Stock-based compensation 13,070,962     13,070,962      
Net loss attributable to common stockholders (88,205,772)       (88,205,772)    
Unrealized gain (loss) on short-term investments, net of tax 7,458         7,458  
Unrealized gain (loss) on investment in affiliated entity, net of tax (1,452,431)         (1,452,431)  
Ending balance (shares) at Dec. 31, 2017   23 90,357,644        
Ending balance at Dec. 31, 2017 $ 142,488,809 $ 0 $ 90,358 $ 665,775,504 $ (523,356,317) $ (117,005) $ 96,269